These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 16924941

  • 1. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 2. [Medication for ADHD and the risk of cardiovascular mortality].
    Kalverdijk LJ, Buitelaar JK, van der Gaag RJ.
    Ned Tijdschr Geneeskd; 2006 Oct 14; 150(41):2283-4; author reply 2284. PubMed ID: 17078147
    [No Abstract] [Full Text] [Related]

  • 3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 14; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 4. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep 14; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 5. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 14; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 6. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M.
    Pediatrics; 2007 Jan 14; 119(1):154-5. PubMed ID: 17200281
    [No Abstract] [Full Text] [Related]

  • 7. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec 14; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 8. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.
    Arch Pediatr; 2014 Jan 14; 21(1):108-12. PubMed ID: 24309201
    [Abstract] [Full Text] [Related]

  • 9. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May 14; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 10. ADHD black box warning: how concerned should we be?
    Cruz R, Kutscher EC.
    S D Med; 2007 Feb 14; 60(2):63, 65. PubMed ID: 17390569
    [No Abstract] [Full Text] [Related]

  • 11. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun 14; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 12. [Graphomotor functions in children with attention deficit hyperactivity disorder (ADHD)].
    Stasik D, Tucha O, Tucha L, Walitza S, Lange KW.
    Psychiatr Pol; 2009 Jun 14; 43(2):183-92. PubMed ID: 19697788
    [Abstract] [Full Text] [Related]

  • 13. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J, Knecht C, Szerman N, Martinez MI.
    CNS Drugs; 2013 Jan 14; 27(1):15-30. PubMed ID: 23160939
    [Abstract] [Full Text] [Related]

  • 14. A case of acute cardiomyopathy and pericarditis associated with methylphenidate.
    Dadfarmay S, Dixon J.
    Cardiovasc Toxicol; 2009 Mar 14; 9(1):49-52. PubMed ID: 19296063
    [Abstract] [Full Text] [Related]

  • 15. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.
    Clin Ther; 2009 Aug 14; 31(8):1844-55. PubMed ID: 19808143
    [Abstract] [Full Text] [Related]

  • 16. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 14; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 17. Cardiac arrest with pulseless electrical activity associated with methylphenidate in an adolescent with a normal baseline echocardiogram.
    Daly MW, Custer G, McLeay PD.
    Pharmacotherapy; 2008 Nov 14; 28(11):1408-12. PubMed ID: 18957001
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 14; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 19. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 14; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 20. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E.
    CMAJ; 2006 Jul 04; 175(1):29. PubMed ID: 16772535
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.